# Tafalgie Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tafalgie-therapeutics

- Industry: Biotechnology
- Headquarters: France
- Website: tafalgie.fr
- Total disclosed funding: $5M
- Latest round: Series A (Feb 27, 2025)
- Investors on record: 2

## About

Founded in 2020 by co-founders Aziz MOQRICH, Stéphane GAILLARD, Eric SCHETTINI, and Laurent LABATUT and based in France, Tafalgie Therapeutics SA is a developer of drugs that can treat pain at all levels without the major drawbacks of existing painkillers. In September 2025, Tafalgie Therapeutics SA raised EUR 18.5 million in series A and venture debt funding from Bpifrance and the European Innovation Council, with participation from individual and other unspecified investors.

Tafalgie Therapeutics is focused on the research and development of advanced-generation analgesic peptides. The medications target a specific protein (TAFA4) involved in pain signaling and prevent both acute and chronic pain without addiction or tolerance issues.  These medications are still under development and not yet available to the public. The company’s product pipeline includes targeted therapeutics for various types of pain, including post-operative pain, rare diseases, and acute and chronic pain. The lead compounds are in different stages of development, from preclinical research to Phase 2 clinical trials.

The company will use the September 2025 funding to advance its leading TT5 drug candidate into Phase 2A clinical trials.

## Funding rounds

- Series A, Feb 27, 2025, $5M — Bpifrance, European Innovation Council

## Investors

- Bpifrance — Series A
- European Innovation Council (https://capitalatlas.ai/funds/european-innovation-council) — Series A